Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 9 studies | 23% ± 9% | |
| pericyte | 6 studies | 22% ± 5% | |
| endothelial cell | 5 studies | 24% ± 8% | |
| epithelial cell | 4 studies | 37% ± 18% | |
| conventional dendritic cell | 3 studies | 24% ± 6% | |
| natural killer cell | 3 studies | 19% ± 1% | |
| ciliated cell | 3 studies | 29% ± 5% | |
| myofibroblast cell | 3 studies | 19% ± 2% | |
| macrophage | 3 studies | 21% ± 2% | |
| dendritic cell | 3 studies | 31% ± 7% | |
| abnormal cell | 3 studies | 19% ± 3% | |
| goblet cell | 3 studies | 22% ± 4% | |
| connective tissue cell | 3 studies | 35% ± 12% | |
| plasmacytoid dendritic cell | 3 studies | 24% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 100% | 4029.34 | 459 / 459 | 100% | 78.56 | 1118 / 1118 |
| esophagus | 100% | 3473.50 | 1445 / 1445 | 100% | 56.69 | 183 / 183 |
| intestine | 100% | 3051.11 | 966 / 966 | 100% | 78.67 | 527 / 527 |
| lung | 100% | 3413.71 | 578 / 578 | 100% | 71.52 | 1155 / 1155 |
| prostate | 100% | 3471.24 | 245 / 245 | 100% | 83.02 | 502 / 502 |
| stomach | 100% | 3394.88 | 359 / 359 | 100% | 67.19 | 286 / 286 |
| thymus | 100% | 6267.62 | 653 / 653 | 100% | 118.74 | 604 / 605 |
| bladder | 100% | 3857.81 | 21 / 21 | 100% | 71.61 | 503 / 504 |
| skin | 100% | 4523.30 | 1809 / 1809 | 100% | 87.49 | 471 / 472 |
| ovary | 100% | 4187.07 | 180 / 180 | 100% | 57.24 | 429 / 430 |
| adrenal gland | 100% | 6788.31 | 258 / 258 | 100% | 59.57 | 229 / 230 |
| kidney | 100% | 3711.13 | 89 / 89 | 99% | 67.78 | 896 / 901 |
| pancreas | 100% | 2566.13 | 328 / 328 | 99% | 79.82 | 177 / 178 |
| uterus | 100% | 3809.02 | 170 / 170 | 99% | 70.37 | 456 / 459 |
| liver | 100% | 3020.63 | 226 / 226 | 98% | 43.46 | 399 / 406 |
| brain | 100% | 2594.04 | 2638 / 2642 | 91% | 48.40 | 645 / 705 |
| adipose | 100% | 4148.88 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 109.72 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 55.99 | 29 / 29 |
| spleen | 100% | 3830.09 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 71.35 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 56.13 | 1 / 1 |
| blood vessel | 100% | 3464.26 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 99% | 1846.58 | 794 / 803 | 0% | 0 | 0 / 0 |
| heart | 99% | 1986.72 | 850 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 80% | 2128.19 | 742 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006220 | Biological process | pyrimidine nucleotide metabolic process |
| GO_0009165 | Biological process | nucleotide biosynthetic process |
| GO_0043174 | Biological process | nucleoside salvage |
| GO_0009972 | Biological process | cytidine deamination |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0070694 | Molecular function | deoxyribonucleoside 5'-monophosphate N-glycosidase activity |
| GO_0004132 | Molecular function | dCMP deaminase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0008270 | Molecular function | zinc ion binding |
| Gene name | DCTD |
| Protein name | dCMP deaminase Deoxycytidylate deaminase (EC 3.5.4.12) (dCMP deaminase) |
| Synonyms | |
| Description | FUNCTION: Catalyzes the deamination of dCMP to dUMP, providing the nucleoside monophosphate substrate for the thymidylate synthase/TYMS . Also, part of a nucleotide salvage pathway that eliminates epigenetically modified 5-hydroxymethyl-dCMP (hmdCMP) in a two-step process entailing deamination to cytotoxic 5-hydroxymethyl-dUMP (hmdUMP), followed by its hydrolysis into 5-hydroxymethyluracil (hmU) and 2-deoxy-D-ribose 5-phosphate (deoxyribosephosphate) . Catalyzes the first step in that pathway, the deamination of 5-hydroxymethyl-dCMP (hmdCMP) . . |
| Accessions | P32321 ENST00000510307.5 ENST00000507543.5 ENST00000513348.5 ENST00000514754.5 ENST00000503820.5 ENST00000507631.5 ENST00000438320.7 [P32321-1] D6R9S0 ENST00000509218.5 D6RAR9 D6RBJ9 D6RJA9 ENST00000512766.5 D6RBN2 D6RD72 D6RAD7 ENST00000503988.1 D6RC36 D6R9P0 ENST00000509757.5 ENST00000500813.6 D6RIG3 ENST00000510370.5 [P32321-1] ENST00000357067.7 [P32321-2] ENST00000503182.5 ENST00000508994.1 |